Abstract:INTRODUCTION: Hepatitis B virus (HBV) infection is a contagious condition posing a major public health risk in various nations including Vietnam. In 2019, the Ministry of Health introduced tenofovir alafenamide (TAF) to treat patients with chronic HBV infection and reduce the long-term toxicity of tenofovir disoproxil fumarate (TDF). This study aimed to assess the effectiveness and safety of these two medications in individuals with HBeAg-positive chronic HBV. METHODS: This retrospective cohort study included data collected from the medical records of patients with chronic HBV who visited the Liver Clinic at University Medical Center HCMC between 2018 and 2020. RESULTS: After two years of treatment, the proportion of HBeAg loss in the TAF group was twice that of the TDF group (22.4% vs. 11.2%), indicating a statistically significant difference in the probability of HBeAg loss (adjusted hazard ratio = 2.22; 95% CI 1.43 to 3.42; p < 0.01). Additionally, there was a statistically significant difference in the rate and ability of antiviral response between patients treated with TAF and TDF (65% vs. 54.5%, respectively; adjusted hazard ratio = 1.34; 95% CI 1.08 to 1.69; p < 0.01). 93.9% of patients achieved the goal of restoring ALT to normal, a higher percentage compared to the 81.2% in the TDF group, and the likelihood of achieving normal ALT levels with TAF was greater compared to those on TDF (adjusted hazard ratio = 1.67; 95% CI 1.38 to 2.01; p < 0.01). Moreover, there was a statistically significant difference in the variation in renal function between the TAF and TDF groups. Serum creatinine levels in the TAF group increased less than those in the TDF group by 0.03 mg/dL every 6 months (95% CI -0.04 to -0.01, p < 0.01), and the eGFR in the TAF group was higher than that in the TDF group every 6 months by 2.78 mL/min/1.73 m 2 (95% CI 0.98 to 4.57, p < 0.01). However, there was no statistically significant difference in the likelihood of HBeAg seroconversion between chronic hepatitis B patients treated with TAF or TDF (adjusted hazard ratio = 1.79; 95% CI 0.91 to 3.53; p = 0.09), nor in the risk of adverse events between the two groups (adjusted odds ratio = 1.34; 95% CI 0.88 to 2.05; p = 0.17). Additionally, although the HBsAg concentration in the TAF group was lower than in the TDF group by an average of 0.05 log10 IU/mL every 6 months (95% CI -0.15 to 0.05), this difference also did not reach statistical significance (p = 0.35). DISCUSSION: TAF has been demonstrated to achieve some therapeutic efficacy goals and reduce nephrotoxicity better than TDF. However, no differences were found in seroconversion or adverse events between the patient groups.

Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir—A Propensity Score–Matched Study

Efficacy and Safety of Tenofovir Disoproxil Treatment for Chronic Hepatitis B Patients with Genotypic Resistance to Other Nucleoside Analogues: A Prospective Study.

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B

Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis

Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B

Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy

Effects of tenofovir disoproxil fumarate on intrahepatic viral burden and liver immune microenvironment in patients with chronic hepatitis B

Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial.

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate Versus Emtricitabine and Tenofovir Disoproxil Fumarate As Treatments for Patients with Chronic Hepatitis B

Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis

Prognosis Comparison Between Chronic Hepatitis B Patients Receiving a Finite Course of Tenofovir and Entecavir Treatment: A Nationwide Cohort Study in Taiwan

Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis

Hepatocellular Carcinoma Incidences and Risk Factors in Hepatitis C Patients: Interferon Versus Direct-Acting Agents

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?

The Use of Tenofovir Disoproxil Fumarate in the Management of eAg-Negative Chronic Hepatitis B Infection

Effect of tenofovir versus entecavir on the long-term prognosis in hepatocellular carcinoma patients with concurrent metabolic dysfunction-associated steatotic liver disease and hepatitis B

Clinical Efficacy And Safety of Long-Term Treatment Of Tenofovir Alafenamide Vs Tenofovir Disoproxil Fumarate for Chronic Hepatitis B in Vietnam

Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study

Protective effect of N-acetylcysteine against hepatocellular carcinoma in hepatitis B virus carriers